Importantly, a newly developed CD6-targeted antibody–drug conjugate (CD6-ADC) using the monoclonal antibody UMCD6 has been found to efficiently treat two pre-clinical models of GVHD [84]; this study suggests that CD6-ADC could be developed as a potential therapeutic agent for selectively eliminating pathogenic T cells and treating GVHD. This evidence concerns the gene CD6 and graft versus host disease.